360 degree trabeculectomy best way to treat congenital glaucoma

Article

Using a microcatheter to perform 360° trabeculectomy is a safer and more consistent way to treat congenital glaucoma than traditional trabeculectomy, according to information presented at this year's meeting of the American Glaucoma Society (AGS).

Using a microcatheter to perform 360º trabeculectomy is a safer and more consistent way to treat congenital glaucoma than traditional trabeculectomy, according to information presented at this year's meeting of the American Glaucoma Society (AGS).

Adam C. Reynolds, MD of the Dean McGee Eye Institute, University of Oklahoma, US and colleagues performed 360º trabeculectomy using the iTrack catheter (iScience Interventional), a laser guided microcatheter designed to pass 360º through Schlemm's canal, in 12 congenital glaucoma eyes (nine patients) where trabeculectomy or goniotomy would have been the traditional surgical approach. Mean IOP of preoperative eyes was 31 mmHg.

In 75% of treated eyes (n=8), 360º trabeculectomy from a single surgical site was performed successfully. Of the remaining eyes, 50% (n=2) had previously undergone goniotomies, but most of the remaining angle (for a minimum of 200º) was cannulated using this method.

After 6.6 months, two eyes had required shunts to be placed. Although the follow-up period was too short to gauge postoperative visual outcomes, corneal clarity has improved and medical therapy been discontinued in the majority of cases. Mean IOP, postoperatively, was 17 mmHg.

The surgeons concluded that this method of treating congenital glaucoma is effective and offers a lower risk of surgical complications, although the follow-up period was too short to make any definitive assessment of long-term outcomes when compared with traditional methods.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.